Marc Tessier-Lavigne Ph.D.
Net Worth
Last updated:
What is Marc Tessier-Lavigne Ph.D. net worth?
The estimated net worth of Dr. Marc Tessier-Lavigne Ph.D. is at least $57,529,989 as of 23 Nov 2022. He owns shares worth $27,681,269 as insider, has earned $29,551,220 from insider trading and has received compensation worth at least $297,500 in Denali Therapeutics Inc..
What is the salary of Marc Tessier-Lavigne Ph.D.?
Dr. Marc Tessier-Lavigne Ph.D. salary is $59,500 per year as Co-Founder, Chairman of Scientific Advisory Board & Independent Director in Denali Therapeutics Inc..
How old is Marc Tessier-Lavigne Ph.D.?
Dr. Marc Tessier-Lavigne Ph.D. is 65 years old, born in 1960.
What stocks does Marc Tessier-Lavigne Ph.D. currently own?
As insider, Dr. Marc Tessier-Lavigne Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 1,870,356 | $14.8 | $27,681,269 |
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Marc Tessier-Lavigne Ph.D. insider trading
Denali Therapeutics Inc.
Dr. Marc Tessier-Lavigne Ph.D. has made 29 insider trades between 2020-2022, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of DNLI stock worth $609,600 on 23 Nov 2022.
The largest trade he's ever made was exercising 400,000 units of DNLI stock on 16 Jun 2020. As of 23 Nov 2022 he still owns at least 1,870,356 units of DNLI stock.
Denali Therapeutics key executives
Denali Therapeutics Inc. executives and other stock owners filed with the SEC:
- Dr. Alexander O. Schuth M.D. (52) Co-Founder, Chief Operating Officer & Sec.
- Dr. Carole Ho (52) Chief Medical Officer & Head of Devel.
- Dr. Marc Tessier-Lavigne Ph.D. (65) Co-Founder, Chairman of Scientific Advisory Board & Independent Director
- Dr. Ryan J. Watts Ph.D. (49) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Steve Edward Krognes (57) Chief Financial Officer & Treasurer